$1.48
-0.15 (-9.20%)
BTMD News9 articles
Danaher Plunges 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares dropped 11% after its biotech segment underperformed expectations, leading to a valuation adjustment. Full-year core growth guidance was narrowed to 3%-4%.
Danaher Tumbles 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares plunged 11% on Tuesday after biotech growth fell short of expectations, prompting a sharp valuation reset even as quarterly revenue and earnings topped forecasts.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
Recursion Pharmaceuticals Rallies as Short Interest and Russell Flows Drive AI-Biotech Surge
Recursion Pharmaceuticals (RXRX) rose 4.7% to $3.98, driven by heavy short interest and Russell index flows. The stock's volume surged above average as the market focused on upcoming clinical catalysts.
Recursion Pharma Rallies Past Biotech ETFs; Insider Sales and Cash Position in Focus
Recursion Pharmaceuticals (RXRX) surged 8% in a four-session week, beating biotech ETFs. Filings show insider sales, while the company's $665M cash position and upcoming data updates remain key.
Legend Biotech Surges 42% on Promising Early CAR-T Data
Legend Biotech shares surged 42% after early Phase 1 data showed all six high-dose patients with relapsed B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy, with five achieving complete responses.
Legend Biotech Surges on Promising Early In Vivo CAR-T Data
Legend Biotech shares soared over 35% after early Phase 1 data showed all six high-dose patients with relapsed/refractory B-cell NHL responded to its in vivo CAR-T drug LB2501, with five complete responses and no relapses as of April 1.
HCW Biologics Rockets 122% as Traders Flock to Micro-Cap Biotech
HCW Biologics shares skyrocketed 122% to $2.35 on Wednesday as traders piled into the micro-cap biotech, fueled by a new stock offering and first-quarter revenue of $6.54 million from a licensing deal.
Edesa Biotech Surges 54% on Renewed ARDS Drug Optimism
Edesa Biotech (EDSA) shares surged 54% on Monday, driven by renewed interest in February data showing paridiprubart reduced 28-day ARDS mortality to 24% from 33%.